Sarah Motta is currently group leader and lead scientist on an ERC and a SNSF funded projects. The projects are focused on the preclinical development and validation of aortic tissue-engineered heart valves suitable for minimally-invasive applications. These prostheses have the unique ability to transform into a fully autologous valve within the body and last for life. In details, the project aims at engineering a novel xenogeneic-free decellularized human matrix and a bioresorbable stent, and finally apply an unconventional bioengineering approach combining in-vitro, in-silico, and in-vivo tissue engineering methods. Since 2018, Sarah is appointed as Research Associate at the Disease Biophysics Group (DBG) at Harvard University as well as at the Wyss Institute of Zurich.